An interventional study of eCoin Peripheral Neurostimulator System in Urge Incontinence, sponsored by Valencia Technologies Corporation. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-03.
Sponsored by Valencia Technologies Corporation · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 135 studies in Urinary Incontinence, Urge with a site in United States — 19 open to participants now, 26 under way, none of them phase 3. Urinary Incontinence, Urge · United States.
Among the 135 studies in Urinary Incontinence, Urge with a site in United States, this one is the 78th largest by enrollment of the 119 interventional ones that give a count, is one of 7 that started in 2023, is one of 72 with no phase, and was the 114th registered.
243 studies on the registry are indexed under Urinary Incontinence, Urge; 39 are open to participants now.
Browse Urinary Incontinence, Urge studies →19 of the 135 studies in Urinary Incontinence, Urge with a site in United States are open now. Recruiting first, the newest first:
Loma Linda University · Sites in United States
Ages 18–89
Axonics, Inc. · Sites in United States, Australia
Ages 18+
Neuspera Medical, Inc. · Sites in United States
Ages 22+
MedtronicNeuro · Sites in United States
Ages 18+
InMode MD Ltd. · Sites in United States
Ages 22–80 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 25 Urinary Incontinence, Urge studies recruiting now, 18 (72%) set no upper age limit and 2 (8%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
135 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10 · Phase 3 14 · Phase 4 19
First in 2003; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 38 is below the median of 86 across 191 interventional studies indexed under Urinary Incontinence, Urge.
Median enrollment 75 across the 119 interventional studies, 47 across the 15 observational. Of the 97 that completed or were terminated, 51 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 135 have an industry lead sponsor. The 10 most frequent:
Valencia Technologies Corporation is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Valencia Technologies Corporation has 4 studies filed under Urinary Incontinence, Urge — fewer than ten, so there is no comparison to draw.
11 of the studies in Urinary Incontinence, Urge with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06797245Medstar Health Research InstituteAPPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women | 2026-11 |
| NCT07387315TriHealth Inc.A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections | 2026-11 |
| NCT07335484Axonics, Inc.Aquarius Pilot Study to Evaluate the New Axonics Trial System | 2026-11 |
| NCT07247136Neuspera Medical, Inc.Study of 30-Minute Stimulation With the Neuspera Sacral Neuromodulation (SNM) System | 2026-11 |
| NCT06186765Axonics, Inc.F15 Recharge Free Axonics SNM System Clinical Study | 2026-12 |
Add all 11 to your calendar (.ics) → With an account.
Among the 135 studies in Urinary Incontinence, Urge with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this prospective, multi-center, double-blinded randomized controlled is to learn about effectiveness and QOL with eCoin at two different amplitude settings in subjects with urge urinary incontincence (UUI). The main question it aims to answer is:
Participants will be implanted with the eCoin device and randomized to either a sensory or subsensory stimulation group and complete voiding diaries and patient reported-outcomes through 3 months of therapy. After 3 months, subjects will be unblinded and reprogramming will be offered. Subjects will be followed for an additional month to a total of 4 months.
Key Inclusion Criteria:
Key Exclusion Criteria:
Individual has lower extremity pathology such as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the sensory treatment arm will be programmed to their sensory threshold.
Device: eCoin Peripheral Neurostimulator System
Participants in the subsensory treatment arm will be programmed to approximately 75% of their sensory threshold.
Device: eCoin Peripheral Neurostimulator System
The eCoin device is a leadless, coin-sized tibial neurostimulator for treatment of urgency urinary incontinence. It emits a dome-shaped electrical field to deliver low-duty cycle stimulation to the tibial nerve. The device is to be implanted under local anesthetic in the lower leg, and once activated delivers automatic 30-minute treatment sessions without the need for patient management.
Change in UUI Episodes Per Day
The primary endpoint is to explore the effect of two different eCoin amplitude settings on the change of UUI episodes per day on a 3-day voiding diary. A negative number shows a reduction in UUI episodes per day which means symptoms have improved since baseline. A positive number shows an increase in UUI episodes per day which means symptoms have worsened since baseline.
Time frame: 3 months post-activation
Change in UUI Episodes Per Day
Change in the number of urgency urinary incontinence episodes per day on a 3-day voiding diary. A negative number shows a reduction in UUI episodes which means symptoms have improved since baseline. A positive number shows an increase in UUI episodes per day which means symptoms have worsened since baseline.
Time frame: 2 months post-activation
Change in UUI Episodes Per Day
A secondary endpoint is to explore the change in UUI episodes per day on a 3-day voiding diary. A negative number shows a reduction in UUI episodes per day which means symptoms have improved since baseline. A positive number shows an increase in UUI episodes per day which means symptoms have worsened since baseline.
Time frame: 4 months post-activation
Change in Overactive Bladder Health Related Quality of Life (HRQL)
Change from baseline in the patient reported quality of life as assessed by the Health Related Quality of Life (HRQL) portion of the Overactive Bladder questionnaire (OABq) survey. Higher scores on the HRQL portion indicate better quality of life. The maximum HRQL domain score is 100 (best) and the minimum HRQL score is 0 (worst). A positive change in score indicates an improvement in quality of life.
Time frame: 2 and 3 months post-activation
Change in Overactive Bladder Health Related Quality of Life (HRQL)
Change from baseline in patient reported quality of life as assessed by the Health Related Quality of Life (HRQL) portion of the Overactive Bladder questionnaire (OABq) survey. Higher scores on the HRQL indicate better quality of life. The maximum HRQL domain score is 100 (best) and the minimum HRQL score is 0 (worst). A positive change in score indicates an improvement in quality of life.
Time frame: 4 months post-activation
| Milestone | Sensory | Subsensory |
|---|---|---|
| Started | 18 | 18 |
| Completed | 17 | 17 |
| Not completed | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 |
The primary endpoint is to explore the effect of two different eCoin amplitude settings on the change of UUI episodes per day on a 3-day voiding diary. A negative number shows a reduction in UUI episodes per day which means symptoms have improved since baseline. A positive number shows an increase in UUI episodes per day which means symptoms have worsened since baseline.
| UUI episodes per day | Sensory | Subsensory |
|---|---|---|
| Change in UUI Episodes Per Day | -2.1 ± 2.42 | -2.73 ± 1.8 |
Change in the number of urgency urinary incontinence episodes per day on a 3-day voiding diary. A negative number shows a reduction in UUI episodes which means symptoms have improved since baseline. A positive number shows an increase in UUI episodes per day which means symptoms have worsened since baseline.
| UUI episodes per day | Sensory | Subsensory |
|---|---|---|
| Change in UUI Episodes Per Day | -2.75 ± 1.9 | -2.14 ± 2.58 |
A secondary endpoint is to explore the change in UUI episodes per day on a 3-day voiding diary. A negative number shows a reduction in UUI episodes per day which means symptoms have improved since baseline. A positive number shows an increase in UUI episodes per day which means symptoms have worsened since baseline.
| UUI episodes per day | Sensory | Subsensory |
|---|---|---|
| Change in UUI Episodes Per Day | -2.59 ± 2.6 | -2.96 ± 2.12 |
Change from baseline in the patient reported quality of life as assessed by the Health Related Quality of Life (HRQL) portion of the Overactive Bladder questionnaire (OABq) survey. Higher scores on the HRQL portion indicate better quality of life. The maximum HRQL domain score is 100 (best) and the minimum HRQL score is 0 (worst). A positive change in score indicates an improvement in quality of life.
| Change in HRQL Score | Sensory | Subsensory |
|---|---|---|
| 2 months | 25.87 ± 21.6 | 22.78 ± 24.19 |
| 3-months | 18.15 ± 22.63 | 22.59 ± 24.95 |
Change from baseline in patient reported quality of life as assessed by the Health Related Quality of Life (HRQL) portion of the Overactive Bladder questionnaire (OABq) survey. Higher scores on the HRQL indicate better quality of life. The maximum HRQL domain score is 100 (best) and the minimum HRQL score is 0 (worst). A positive change in score indicates an improvement in quality of life.
| Change in HRQL Score | Sensory | Subsensory |
|---|---|---|
| Change in Overactive Bladder Health Related Quality of Life (HRQL) | 22.03 ± 25.56 | 32.09 ± 26.2 |
Collected over 4 months post-activation. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sensory | 0/18 (0%) | 0/18 (0%) | 7/18 (38.9%) |
| Subsensory | 0/18 (0%) | 0/18 (0%) | 6/18 (33.3%) |
| Event | Sensory | Subsensory |
|---|---|---|
| Incision Site Impaired HealingInjury, poisoning and procedural complications | 2/18 | 0/18 |
| Site Incision PainInjury, poisoning and procedural complications | 2/18 | 0/18 |
| Medical Device Site ErythemaGeneral disorders | 0/18 | 1/18 |
| Post Procedural DiscomfortGeneral disorders | 0/18 | 1/18 |
| Incision Site DischargeInjury, poisoning and procedural complications | 1/18 | 0/18 |
| Implant Site OedemaInjury, poisoning and procedural complications | 1/18 | 1/18 |
| Incision Site HaemorrhageInjury, poisoning and procedural complications | 0/18 | 1/18 |
| Incision Site Cellulitis, Medical Device Site CellulitisInfections and infestations | 1/18 | 0/18 |
| Postoperative Wound InfectionInjury, poisoning and procedural complications | 0/18 | 1/18 |
| Incision Site Pain, Implant Site BruisingInjury, poisoning and procedural complications | 0/18 | 1/18 |
The number of baseline participants refers to the number of participants who were implanted and randomized into a study arm.
| Age, Continuous(years) | Sensory | Subsensory | Total |
|---|---|---|---|
| Mean | 66 ± 13 | 65 ± 14 | 66 ± 13 |
| Sex: Female, Male(Participants) | Sensory | Subsensory | Total |
|---|---|---|---|
| Female | 16 | 16 | 32 |
| Male | 2 | 2 | 4 |
| Ethnicity (NIH/OMB)(Participants) | Sensory | Subsensory | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 18 | 15 | 33 |
| Unknown or Not Reported | 0 | 2 | 2 |
| Race (NIH/OMB)(Participants) | Sensory | Subsensory | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 17 | 15 | 32 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Region of Enrollment(participants) | Sensory | Subsensory | Total |
|---|---|---|---|
| United States | 18 | 18 | 30 |
| Smoking Status, Current Smoker(Participants) | Sensory | Subsensory | Total |
|---|---|---|---|
| Count of participants | 0 | 0 | 0 |
| Baseline UUI Episodes per Day(UUI Episodes per day) | Sensory | Subsensory | Total |
|---|---|---|---|
| Mean | 4.91 ± 2.12 | 5.9 ± 3.01 | 5.39 ± 2.6 |
| Baseline HRQL Score(HRQL Score) | Sensory | Subsensory | Total |
|---|---|---|---|
| Mean | 53.07 ± 18.67 | 53.13 ± 22.13 | 53.1 ± 20.11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2023 to primary completion in Apr 2024, 10 months.
Results were first posted in Nov 2025, 1 year 6 months after primary completion.
Of 77 interventional studies with no phase under Urinary Incontinence, Urge, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 10 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Valencia Technologies Corporation